FibroGen Stock News

Company hits 52-week high of $12.25 Continue reading...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc...

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Anyone researching FibroGen, Inc. (NASDAQ:FGEN) might want to consider the historical volatility of the share price...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

FibroGen initiated with a Market Perform at Cowen Cowen FGEN

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (NASDAQ:FGEN) is set to issue its quarterly earnings data after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

Bank of America assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a report published on Monday, Benzinga reports. The brokerage issued a neutral rating and a $45.00 price objective on the biopha